Device Trial Radar · NCT01403077
480 Biomedical Bioresorbable Scaffold System in the Treatment of de Novo Superficial Femoral Artery (SFA) Lesions
Last checked: Nov 20, 2026Latest source record: Sep 6, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Oct 2011
Primary completion
Mar 2014
Study completion Oct 2015
Sponsor
- Lead sponsor
- 480 BiomedicalNot on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 27, 2011
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an initial evaluation of the 480 Biomedical Bioresorbable Scaffold System for the treatment of subjects with de novo native superficial femoral artery lesions.
Conditions
- Superficial Femoral Artery Lesions
- Atherosclerosis of Femoral Artery
Interventions
480 Biomedical Bioresorbable Scaffold SystemDevice
480 Biomedical Bioresorbable Scaffold System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major adverse events at 6 months post procedureTime frame: 6 Months
Locations
6 sites in 4 countries. Site status is shown where the registry gives one.
The Alfred
Melbourne, Australia
Universitäts Klinikum Graz
Graz, Austria
Universitaet Freiburg-Bad Krozingen
Freiburg im Breisgau, Germany
3 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.